Filtered By:
Therapy: Stem Cell Therapy

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 67851 results found since Jan 2013.

An Iterative Formative Evaluation of Medical Education for Multiple Myeloma Patients Receiving Autologous Stem Cell Transplant
AbstractMultiple myeloma (MM) is an incurable cancer characterized by abnormal plasma cells in the bone marrow, resulting in increased risk of infection. Autologous stem cell transplant (ASCT) is the most effective treatment for MM, but successful transplant requires the patient and caregiver to learn and independently implement medical tasks. The Ready for Transplant (R4T) ethnographic-based formative evaluation includes evaluation of ongoing patient education and the addition of novel supplemental educational videos that patients can review before in-person transplant education. To evaluate R4T, a formative evaluation in...
Source: Journal of Cancer Education - September 24, 2020 Category: Cancer & Oncology Source Type: research

Medical students and controversial ethical issues: results from the multicenter study SBRAME
Conclusion: The current study reveals MS have different opinions regarding controversial ethical issues. Noteworthy, these opinions seem to be shaped more by university characteristics and religious beliefs than socio-demographic data.
Source: BMC Medical Ethics - December 15, 2014 Category: Medical Ethics Authors: Giancarlo LucchettiLeandro de OliveiraJosé LeiteAlessandra Lucchetti Source Type: research

A scoping review of regenerative medicine in medical education
Stem cell therapeutics and regenerative medicine have taken a strong foothold in biomedicine. However, most physicians are currently not adequately prepared to identify, refer, and deliver safe regenerative th...
Source: BMC Medical Education - November 5, 2022 Category: Universities & Medical Training Authors: Rachita Pandya and Zohray Talib Tags: Research Source Type: research

Basic Concepts in Stem Cells: Integrative Medicine Grand Rounds, March 4th
Please join us for Integrative Medicine Grand Rounds on Tuesday, March 4, 2014 in  925 Chestnut Street, 2nd floor conference room from 8:00-9:00 am. Please note the venue for this exciting program.  Anthony J. Bazzan, MD, ABIHM. is presenting and the title of his presentation is: “Basic Concepts in Stem Cells” Dr. Anthony Bazzan is a leading physician at the Myrna Brind Center of Integrative Medicine and co-author of the popular press book, The Great Life Makeover (Harper-Collins). He is board certified in Internal Medicine and Geriatric Medicine, and is a national expert on integrative treatments for men...
Source: What's New on JEFFLINE - February 25, 2014 Category: Databases & Libraries Authors: lgm002 Tags: All News Clinicians Researchers Students Teaching Faculty Source Type: news

Primary myelofibrosis: 2013 update on diagnosis, risk‐stratification, and management
Disease overviewPrimary myelofibrosis (PMF) is a myeloproliferative neoplasm characterized by stem cell‐derived clonal myeloproliferation, abnormal cytokine expression, bone marrow fibrosis, anemia, splenomegaly, extramedullary hematopoiesis (EMH), constitutional symptoms, cachexia, leukemic progression, and shortened survival. DiagnosisDiagnosis is based on bone marrow morphology. The presence of fibrosis, JAK2/MPL mutation, or +9/13q− cytogenetic abnormality is supportive but not essential for diagnosis. Prefibrotic PMF mimics essential thrombocythemia in its presentation and the distinction is prognostically relevan...
Source: American Journal of Hematology - January 24, 2013 Category: Hematology Authors: Ayalew Tefferi Tags: A Continuing Medical Education Series Source Type: research

Multiple myeloma: 2013 update on diagnosis, risk‐stratification, and management
Disease overviewMultiple myeloma accounts for approximately 10% of hematologic malignancies. DiagnosisThe diagnosis requires 10% or more clonal plasma cells on bone marrow examination or a biopsy proven plasmacytoma plus evidence of associated end‐organ damage. In addition, the presence of 60% or more clonal plasma cells in the marrow is also considered as myeloma regardless of the presence or absence of end‐organ damage. Risk stratificationIn the absence of concurrent trisomies, patients with 17p deletion, t(14;16), and t(14;20) are considered to have high‐risk myeloma. Patients with t(4;14) translocation are consid...
Source: American Journal of Hematology - February 25, 2013 Category: Hematology Authors: S. Vincent Rajkumar Tags: A Continuing Medical Education Series Source Type: research

Immunoglobulin light chain amyloidosis: 2013 update on diagnosis, prognosis, and treatment
Disease OverviewImmunoglobulin (Ig) light chain amyloidosis is a clonal, nonproliferative plasma cell disorder in which fragments of Ig light chain are deposited in tissues. Clinical features depend on organs involved but can include restrictive cardiomyopathy, nephrotic syndrome, hepatic failure, peripheral/autonomic neuropathy, and atypical multiple myeloma. DiagnosisTissue biopsy stained with Congo red demonstrating amyloid deposits with apple‐green birefringence is required for diagnosis. Invasive organ biopsy is not required because amyloid deposits can be found in bone marrow biopsy or subcutaneous fat aspirate in ...
Source: American Journal of Hematology - April 18, 2013 Category: Hematology Authors: Morie A. Gertz Tags: A Continuing Medical Education Series Source Type: research

Waldenström macroglobulinemia: 2013 update on diagnosis, risk stratification, and management
Disease OverviewWaldenström macroglobulinemia (WM) is a lymphoplasmacytic lymphoma with immunoglobulin M (IgM) monoclonal protein. Clinical features include anemia, thrombocytopenia, hepatosplenomegaly, and lymphadenopathy. DiagnosisThe presence of IgM monoclonal protein associated with ≥10% clonal lymphoplasmacytic cells in bone marrow confirms the diagnosis. Risk StratificationAge, hemoglobin level, platelet count, β2 microglobulin, and monoclonal IgM concentrations are characteristics required for prognosis. Risk‐Adapted TherapyNot all patients who fulfill WM criteria require therapy; these patients can be observe...
Source: American Journal of Hematology - June 20, 2013 Category: Hematology Authors: Morie A. Gertz Tags: Annual Clinical Updates in Hematological Malignancies: A Continuing Medical Education Series Source Type: research

Chronic myelomonocytic leukemia: 2013 update on diagnosis, risk stratification, and management
Disease overviewChronic myelomonocytic leukemia (CMML) is a clonal hematopoietic stem cell disorder that is classified as a myelodysplastic/myeloproliferative neoplasm by the 2008 World Health Organization classification of hematopoietic tumors. It is characterized by absolute monocytosis (>1 × 109/L) in the peripheral blood that persists for at least 3 months. DiagnosisThe diagnosis of CMML rests on a combination of morphologic, histopathologic and chromosomal abnormalities in the bone marrow. It is important to exclude other myeloproliferative neoplasms and infectious/autoimmune conditions that can cause monocyto...
Source: American Journal of Hematology - October 24, 2013 Category: Hematology Authors: Sameer A. Parikh, Ayalew Tefferi Tags: Annual Clinical Updates in Hematological Malignancies: A Continuing Medical Education Series Source Type: research

Mantle cell lymphoma: 2013 Update on diagnosis, risk‐stratification, and clinical management
Disease OverviewMantle cell lymphoma (MCL) is a non‐Hodgkin lymphoma characterized by involvement of the lymph nodes, spleen, blood, and bone marrow with a short remission duration to standard therapies and a median overall survival of 4–5 years. DiagnosisDiagnosis is based on lymph node, bone marrow, or tissue morphology of centrocytic lymphocytes, small cell type, or blastoid variant cells. A chromosomal translocation t(11:14) is the molecular hallmark of MCL, resulting in the overexpression of cyclin D1. Cyclin D1 is detected by immunohistochemistry in 98% of cases. The absence of SOX‐11 or a low Ki‐67 may corre...
Source: American Journal of Hematology - November 22, 2013 Category: Hematology Authors: Julie M. Vose Tags: Annual Clinical Updates in Hematological Malignancies: A Continuing Medical Education Series Source Type: research

Hodgkin lymphoma: 2014 update on diagnosis, risk‐stratification, and management
Disease overview: Hodgkin lymphoma (HL) is an uncommon B‐cell lymphoid malignancy affecting 9,200 new patients annually and representing approximately 11.5% of all lymphomas in the United States. Diagnosis: HL is composed of two distinct disease entities; the more commonly diagnosed classical HL and the rare nodular lymphocyte‐predominant HL. Nodular sclerosis, mixed cellularity, lymphocyte depletion, and lymphocyte‐rich HL are subgroups under the designation of classical HL. Risk stratification: An accurate assessment of the stage of disease in patients with HL is critical for the selection of the appropriate therap...
Source: American Journal of Hematology - June 20, 2014 Category: Hematology Authors: Stephen M. Ansell Tags: A Continuing Medical Education Series Source Type: research

Multiple myeloma: 2014 Update on diagnosis, risk‐stratification, and management
Disease overview: Multiple myeloma accounts for approximately 10% of hematologic malignancies. Diagnosis: The diagnosis requires 10% or more clonal plasma cells on bone marrow examination or a biopsy proven plasmacytoma plus evidence of associated end‐organ damage. If end‐organ damage is not present, the presence of 60% or more clonal plasma cells in the marrow is also considered as myeloma. Risk stratification: In the absence of concurrent trisomies, patients with 17p deletion, t(14;16), and t(14;20) are considered to have high‐risk myeloma. Patients with t(4;14) translocation are considered intermediate‐risk. All...
Source: American Journal of Hematology - September 16, 2014 Category: Hematology Authors: S. Vincent Rajkumar Tags: A Continuing Medical Education Series Source Type: research

Mantle Cell Lymphoma: 2015 Update on Diagnosis, Risk‐Stratification and Clinical Management
This article is protected by copyright. All rights reserved.
Source: American Journal of Hematology - June 23, 2015 Category: Hematology Authors: Julie M. Vose Tags: Annual Clinical Updates in Hematological Malignancies: A Continuing Medical Education Series Source Type: research

POEMS syndrome: Update on diagnosis, risk‐stratification, and management
Disease overview: POEMS syndrome is a paraneoplastic syndrome due to an underlying plasma cell neoplasm. The major criteria for the syndrome are polyradiculoneuropathy, clonal plasma cell disorder (PCD), sclerotic bone lesions, elevated vascular endothelial growth factor, and the presence of Castleman disease. Minor features include organomegaly, endocrinopathy, characteristic skin changes, papilledema, extravascular volume overload, and thrombocytosis. Diagnoses are often delayed because the syndrome is rare and can be mistaken for other neurologic disorders, most commonly chronic inflammatory demyelinating polyradiculone...
Source: American Journal of Hematology - September 1, 2015 Category: Hematology Authors: Angela Dispenzieri Tags: Annual Clinical Updates in Hematological Malignancies: A Continuing Medical Education Series Source Type: research

Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring
Disease overview: Chronic Myeloid Leukemia (CML) is a myeloproliferative neoplasm with an incidence of 1‐2 cases per 100,000 adults. It accounts for approximately 15% of newly diagnosed cases of leukemia in adults. Diagnosis: CML is characterized by a balanced genetic translocation, t(9;22)(q34;q11.2), involving a fusion of the Abelson gene (ABL1) from chromosome 9q34 with the breakpoint cluster region (BCR) gene on chromosome 22q11.2. This rearrangement is known as the Philadelphia chromosome. The molecular consequence of this translocation is the generation of a BCR‐ABL1 fusion oncogene, which in turn translates into...
Source: American Journal of Hematology - January 22, 2016 Category: Hematology Authors: Elias Jabbour, Hagop Kantarjian Tags: Annual Clinical Updates in Hematological Malignancies: A Continuing Medical Education Series Source Type: research